his document provides a summary of results from the article that evaluated the safety and efficacy of the fixed and individualized starting doses of niraparib in the PRIMA study. The original article was published in the journal Cancer in March 2023.This Plain Language Summary of Publication article from Future Oncology summarises a study called PRIMA. The study looked at whether giving people with advanced ovarian cancer an individualized dose of the medication niraparib, based on how much they weighed and their blood test, would improve patient safety without changing the efficacy (or effectiveness) of the drug.

Visit the Future Medicine using the link to read the article.

The original article on which this summary is based is called ‘Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: results from the PRIMA/ENGOT-OV26/GOG-3012 trial’ and was published in Cancer. 

Visit the American Cancer Society Journals using the link to read the article.